Skip to Contents

Spectrum Pharmaceuticals Announces Commercial Availability of ROLVEDON™(eflapegrastim-xnst) Injection

2022.10.24
share on Facebook share on Twitter copy url
Rolvedon(최종).jpg

Spectrum Pharmaceuticals Announces Commercial Availability of ROLVEDON™(eflapegrastim-xnst) Injection

PREV Spectrum Pharmaceuticals Receives FDA Approval for ROLVEDON™ (eflapegrastim-xnst) Injection LIST NEXT Hanmi Pharmaceutical’s revenue hit a record high at \1.33 tril. in 2022